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Structural basis of Ac-SDKP 
hydrolysis by Angiotensin-I 
converting enzyme
Geoffrey Masuyer1,*,†, Ross G. Douglas2,*,‡, Edward D. Sturrock2 & K. Ravi Acharya1
Angiotensin-I converting enzyme (ACE) is a zinc dipeptidylcarboxypeptidase with two active domains 
and plays a key role in the regulation of blood pressure and electrolyte homeostasis, making it the 
principal target in the treatment of cardiovascular disease. More recently, the tetrapetide N-acetyl-
Ser–Asp–Lys–Pro (Ac-SDKP) has emerged as a potent antifibrotic agent and negative regulator of 
haematopoietic stem cell differentiation which is processed exclusively by ACE. Here we provide a 
detailed biochemical and structural basis for the domain preference of Ac-SDKP. The high resolution 
crystal structures of N-domain ACE in complex with the dipeptide products of Ac-SDKP cleavage 
were obtained and offered a template to model the mechanism of substrate recognition of the 
enzyme. A comprehensive kinetic study of Ac-SDKP and domain co-operation was performed and 
indicated domain interactions affecting processing of the tetrapeptide substrate. Our results further 
illustrate the molecular basis for N-domain selectivity and should help design novel ACE inhibitors 
and Ac-SDKP analogues that could be used in the treatment of fibrosis disorders.
Angiotensin-1-converting enzyme (ACE, EC 3.4.15.1) is a zinc peptidase and a key enzyme in 
cardio-vascular physiology1,2. ACE is a central component of the Renin-Angiotensin-Aldosterone System 
(RAAS), wherein it converts angiotensin I into the vasoactive peptide hormone angiotensin II (AngII)3,4. 
Interestingly, ACE consists of two catalytically active domains5,6 (referred to as the N- and C-domains 
based on location on the polypeptide chain) that, while very similar in sequence and structural topology, 
display differences in substrate processing abilities6–8. ACE is also able to cleave the vasodilatory peptide 
bradykinin and therefore enhance the blood pressure response9. In addition to the cleavage of vasopep-
tides, ACE is able to cleave a variety of peptides that are outside of its blood pressure role. While these 
are not the most well-known substrates for ACE, many of these have important physiological roles and 
therefore warrant careful study.
N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) is specifically cleared by ACE10. This process has been reported 
to be carried out predominantly by the N-domain7. Ac-SDKP was originally discovered as a potent 
inhibitor of bone marrow derived stem cell differentiation through inhibition of the G1-S phase tran-
sition11,12. This suggested a possible role of Ac-SDKP as a co-treatment to reduce the treatment associ-
ated severity of some chemotherapies due to this peptide being able to keep stem cells in the quiescent 
state13. Later findings indicated that Ac-SDKP also possesses potent anti-fibrotic and anti-inflammatory 
effects in numerous tissues including heart, liver, kidney and lung14–22. Ac-SDKP is able to blunt the 
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Smad signalling effects of transforming growth factor-β , a prominent fibrosis marker23,24. Thus, Ac-SDKP 
appears to have a prominent physiological role.
The N- and C-domains of ACE have been shown to display negative co-operativity in substrate 
hydrolysis25–27. While this is observed with many synthetic and naturally occurring peptides, not all 
substrates displayed such an effect27. To date, no studies have been performed on the physiologically 
relevant substrate Ac-SDKP.
The X-ray crystal structures of both individual homologous ACE domains have been previously 
determined28,29 and more recently the structure of N-domain in complex with the phosphinic tripep-
tide RXP40730 highlighted the structural requirements for domain specific inhibition. Furthermore, the 
structure of the C-domain in complex with AngII31 gave the first insight into the mechanism of peptide 
recognition by ACE and revealed the regulatory role of AngII on the enzyme’s activity. Studying the 
mechanisms of peptide recognition for each domain of ACE should therefore help our understanding of 
substrate selectivity and lead to the design of better inhibitors.
The purpose of this study was to understand the kinetic nature of Ac-SDKP hydrolysis and the 
structural basis for its interaction with the N-domain of ACE. The high resolution (1.8 Å) X-ray crystal 
structures of the N-domain in complex with the two products of Ac-SDKP cleavage, the dipeptides 
Ac-SD and KP, were determined. The extent of domain interaction during substrate hydrolysis and the 
domain selectivity of these processes were further assessed using a fluorescamine assay. Together the 
data reported here allowed the construction of a comprehensive model of N-domain selective substrate 
recognition and peptidase activity.
Results
Structure of the Ac-SDKP:N-domain complexes. Co-crystallisation experiments were carried out 
to assess the interaction between the N-domain and tetrapeptide Ac-SDKP. Surprisingly, two crystal 
forms were obtained (Table 1). One form presented the same cell dimensions as the previously described 
minimally glycosylated N-domain30 with 2 chains per asymmetric unit in P1. The structure at 1.8 Å 
showed electron difference density within the catalytic channel (Fig. 1A), which was interpreted as the 
Ac-SD product, resulting from the enzymatic reaction. The structure from the second crystal form was 
solved at a similar resolution, in space group P1 with larger cell dimensions, fitting 4 molecules per 
asymmetric unit. No significant conformational changes were observed for the N-domain, with only 
the expected N-terminal hinge region showing signs of disorder in one of the four molecules. However, 
this crystal form did present an alternative and unambiguous difference electron density at the active 
site, with the map clearly showing the dipeptidyl carboxypeptidase product of Ac-SDKP hydrolysis (KP, 
Fig. 1A). The two different fragments occupy a similar position within the S1′ -S2′ sub-pockets while only 
interacting with the zinc ion through water-mediated interactions.
The two peptides have their C-terminal end strongly anchored by hydrogen bonds with residues 
Lys489, Tyr498 and Gln259 forming the S2′ site, amino acids previously shown to be key anchoring 
residues (Fig. 1B). The aromatic Phe435 and Phe505 also stabilise this end of the peptide by hydrophobic 
interaction with the Pro or Asp side chains of the substrate. The acidic group of the substrate Asp showed 
signs of flexibility (Fig. 1A), but may make further water-mediated contacts with the backbone of sur-
rounding enzyme residues Glu431, Thr358 and the Ser260 hydroxyl group. The main difference between 
the two peptidic substrate fragments resides at their first residue due to the presence of the N-acetyl 
group on the serine. With the Lys-Pro fragment, the lysine backbone follow a similar bonding pattern to 
what was observed in the C-domain:Ang II structure, with its oxygen being stabilised by multiple hydro-
gen bonds with enzyme residues His331, His491 and Tyr501 (Fig. 1B) and its amino group interacting 
with the catalytic site. The long side chain can make further polar connection directly with Thr358 and 
water bridges with Asp354, Gln355 and Ser260. On the other hand, the N-acetyl-serine (AcS), of the 
Ac-Ser-Asp fragment, presents a different orientation. Its Hydroxyl side chain makes direct electrostatic 
contacts with His331, His491 and Tyr501, as well as a water-mediated interaction with Zn2+. The AcS 
amino group interacts with a single water molecule itself connected to Thr358 (main chain) and Asp393. 
The acetyl moiety may be stabilised in the small hydrophobic area composed of Ala332 and Thr358.
Kinetics of Ac-SDKP hydrolysis by ACE. Kinetic analysis was performed to assess the selectivity 
and possible co-operativity of the N- and C-domains in Ac-SDKP processing. Individual N-domain and 
C-domain constructs (Fig. 2A) displayed comparable Km values of 199.6 μ M and 138.2 μ M, respectively 
(Table 2). The individual N-domain had a turnover rate that was approximately 3-fold higher than that 
of the C-domain, confirming the N-domain preference for Ac-SDKP, albeit lower than original reports.
Wild-type sACE, with both domains active, displayed a Km value of 239.5 μ M while retaining a kcat 
value (per mole active site) similar to the individual N-domain. Thus, the combined domain turnover 
rate of sACE (25.2 s−1) was slightly higher than the sum of the kcat values for the individual domains.
In order to further delineate domain selectivity and assess the activity of domain active sites in full 
length sACE, C-sACE and N-sACE enzymes (these constructs are full length sACE molecules where one 
of the two active sites has been inactivated by mutation) were employed (Fig. 2A). Interestingly, the Km 
values of the two domain (X-sACE) enzymes were approximately 3-fold higher than their single domain 
counterparts, and twice that of wild-type sACE, again showing an effect of domain interaction on sub-
strate on-off rates. The kcat values were approximately 2-fold higher in C-sACE and N-sACE constructs 
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than their respective single domains, which may be indicative of an inter-domain influence on substrate 
release. Overall, this resulted in a similar catalytic efficiency between the individual N-domain and the 
same domain in full length form (N-sACE), whereas C-sACE was approximately half that of its single 
domain counterpart (that is, the individual C-domain, Fig. 2B).
So as to better appreciate the role of the C-domain in the full length molecule, the CC-sACE mole-
cule, comprising two active C-domains connected with the interdomain linker (Fig. 2A), was character-
ised in terms of Ac-SDKP kinetics. This enzyme showed an increased Km compared to wild-type sACE 
but in a similar range to that of the other full length constructs (Table 2). Interestingly, the turnover rate 
per unit active site of CC-sACE (19.4 s−1) showed a two-fold increase compared to C-sACE (8.2 s−1). The 
resulting improved catalytic efficiency therefore suggests a role of the N-domain in lowering C-domain 
activity in the full length somatic enzyme towards the substrate.
Modelling of the Ac-SDKP substrate interaction with ACE.  The crystal structure of the N-domain 
with the KP fragment gave useful insight into the peptide binding mechanism and allowed us to propose 
a model for the full substrate interaction (Fig. 3). The lysyl-proline-bound structure was used as the basis 
of the superposition with the C-domain:AngII (inhibitory peptide resulting from angiotensin I cleavage) 
structure. The C-terminal end of the Ac-SDKP peptide presents a conserved peptide binding mechanism 
between the two domains and was thus the best anchor on which to build the complete model (Fig. 4). 
The C-domain:AngII structure also shows many of the same residues between the two domain inter-
acting along the peptide backbone, so that the rest of the Ac-SDKP peptide was docked based on this 
mechanism. The Ac-SDKP models for both domains were then refined using the Rosetta FlexPepDock 
server (which uses a Monte-Carlo with minimization approach)32. The tetrapeptide fits well within the 
N-dom:Ac-SD N-dom:KP
Resolution (Å) 1.8 1.8
Space group P1
Cell dimensions and angles  
Number of molecules/asymmetric unit
a = 73, b = 77, c = 83 Å; 
α = 89, β = 64, γ = 75°  
2
a = 73, b = 102, c = 115 Å; 
α = 85, β = 86, γ = 82°  
4
Total/Unique reflections 419,370  130,327
936,596  
293,868
Completeness (%)a 90 (58) 97 (96)
Rmergea,b 10.9 (64.9) 10.3 (70.2)
Rpima,c 7.1 (43.9) 6.8 (45.7)
I/σ (I)a 6.1 (1.6) 6.2 (1.5)
Rcrystd 20.2 20.7
Rfreee 22.8 23.5
RMSD in bond lengths (Å) 0.010 0.007
RMSD in bond angles (°) 1.37 1.18
B- factor statistics (Å2)
Protein all atoms (per chain) 24.7/30.2 30.3/31.3/25.9/25.8
Protein main chain atoms (per chain) 23.8/29.4 29.6/30.7/25.2/25.2
Protein side chain atoms (per chain) 25.7/31.0 31.0/31.8/26.5/26.5
Peptide atoms (per chain) 42.0/39.9 25.9/26.0/25.6/24.1
Solvent atoms 32.2 32.1
Zn2+/Cl− ions 17.8/19.1 20.6/20.8
Glycosylated carbohydrate atoms 64.3 56.1
Ramachandran statistics (Molprobity)
Favored 98.1% 98.1%
Outliers 0.3% 0.1%
PDB code 4ufa 4ufb
Table 1.  Crystallographic statistics of N-domain ACE in complex with Ac-SDKP fragments. aValues in 
parentheses refer to the highest resolution shell. bRmerge = Σ Σ i|Ih − Ihi|/Σ Σ iIh, where Ih is the mean intensity 
for reflection h. cRpim = Σ h (1/nh − 1) Σ l |Ihl − (Ih)|/Σ hΣ l(Ih). dRcryst = Σ ‖ Fo| − |Fc‖ /Σ |Fo|, where Fo and Fc are 
measured and calculated structure factors, respectively. eRfree = Σ ‖ Fo| − |Fc|/Σ |Fo|, calculated from 5% of the 
reflections selected randomly and omitted during refinement.
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narrow catalytic channel by interacting with ACE domain active sites through its backbone from P2′ to 
P1, and additional contacts with the P2 Ser and the corresponding N-domain subsite. The acetyl group 
can be easily accommodated within the wide S2 pocket (Figs 3 and 4). In order to assess the preference 
Figure 1. Mechanism of Ac-SDKP fragments binding to N-domain ACE. (A) Portions of the electron 
density map at the site of the bound peptides with left, Ac-SD, and right, KP. The maps were generated using 
REFMAC561 and correspond to the difference weighted 2mFo-DFc density map, contoured at 1.0σ level, in 
which the peptide atoms were omitted. N-dom in cyan (interacting residues in stick representation), bound 
dipeptides in grey stick, catalytic zinc ion and water molecules as grey and red spheres respectively. (B) 
Schematic of peptide binding to N-ACE. Interactions were calculated with LigPlot+ 64. (C) Superposition of 
the dipeptide Ac-SD and KP structures. Ac-SD and KP are presented in black and grey sticks, respectively.
Figure 2. Analysis of ACE catalytic efficiency on Ac-SDKP. (A) Details of ACE constructs. The wild-type 
ACE (sACE) contains a signal peptide (light grey), the two homologous ectodomains (N-domain in cyan 
and C-domain in blue), the transmembrane domain (dark grey) is also indicated. Inactive domains are 
crossed over. (B) Catalytic efficiency of ACE on Ac-SDKP.
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of Ac-SDKP for the N-domain, the models were compared to the crystal structures of the N-domain with 
RXP 407 (an N-domain specific inhibitor33) and C-domain with AngII (which shows C-domain selectiv-
ity34) (Fig. 4). Previous structural analysis30 has highlighted the high degree of conservation between the 
two domains within the S’ binding sites (Table 3). This is important since it highlights the conservation 
of essential residues for a general role in substrate binding. The specificity for Ac-SDKP appears to reside 
mostly at the S2 subsite. This subsite, while cavernous, provides contacts in the N-domain that could 
explain partial N-domain preference of this substrate. There, the hydroxyl group of Ac-Ser is within 
hydrogen bonding distance of conserved residue His388. The non-conserved Tyr369 can also provide 
further electrostatic potential compared to the C-domain Phe391, and has been identified previously as a 
key residue for ligand selectivity35,36. Furthermore, the polar (N-domain) Thr496 may provide additional 
interaction with the substrate Asp side chains compared to the C-domain enzyme residue Val518. In the 
P1′ pocket, our structure with Lys-Pro shows that the dipeptide’s ε -amino group can interact with Thr358 
which is also not conserved in C-domain ACE (Val380). It should be added that water molecules are 
expected to play a significant role in peptide binding, as illustrated by several water-mediated bonds in 
the crystal structures presented here (Fig. 1), but were not included in the models for practical reasons.
ACE belongs to the gluzincin family of metalloproteases and catalysis is expected to follow a general 
base-type mechanism. The structures determined here allow us to more accurately predict the substrate 
hydrolysis mechanism employed by ACE. The cleavage of Ac-SDKP is predicted to happen after dis-
placement of the zinc-bound water molecule which then attacks the scissile carbonyl bond to form an 
oxyanion (Fig. 5). The nucleophilic attack is enhanced with the water being coordinated by the active site 
Glu362. The resulting intermediate is likely stabilised by Tyr501. As mentioned previously, chloride has 
an important effect on ACE activity which is also substrate-dependent in the C-domain37. The function 
of chloride in N-ACE is less understood, but it is unlikely to affect substrate specificity. However, a role 
Enzyme kcat (s−1) Km (μM) kcat/Km (s−1.M−1)
N-dom 14.2 ± 1.2 199.6 ± 25.5 (0.72 ± 0.06) × 105
C-dom 4.8 ± 0.6 138.2 ± 20.3 (0.35 ± 0.01) × 105
sACE 12.7 ± 0.4 239.5 ± 29.4 (0.54 ± 0.06) × 105
N-sACE 34.0 ± 3.9 493.8 ± 79.3 (0.70 ± 0.04) × 105
C-sACE 8.2 ± 0.5 436.3 ± 33.4 (0.188 ± 0.002) × 105
CC-sACE 19.4 ± 0.8 503.8 ± 31.6 (0.39 ± 0.03) × 105
Table 2.  Kinetic parameters of Ac-SDKP hydrolysis by different ACE enzymes. Turnover rates were 
normalised to activity per unit active site for enzymes containing two functional domains (sACE and  
CC-sACE).
Figure 3. Modelling of Ac-SDKP binding to ACE. (A) Ac-SDKP was manually docked within the 
catalytic channel of N-dom based on the KP complex structure. The model was refined using the Rosetta 
FlexPepDock server32. N-dom is shown in cyan, and Ac-SDKP in grey stick. (B) Close up view of Ac-SDKP 
within the catalytic channel, surface charged was calculated with the PyMol/APBS tool65. (C) Comparison 
of Ac-SDKP models bound to N- and C-domain ACE. N-dom in cyan, C-dom in blue; Ac-SDKP in grey 
and purple in for the N- and C-domain models, respectively. Residues involved in substrate interaction are 
labelled with their protein respective colour.
www.nature.com/scientificreports/
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for the direct involvement of the conserved chloride-coordinating Arg500 should not be excluded as it 
is close to the active site and seen making a water-mediated interaction with Tyr501.
Figure 4. Comparison of domain specific substrate and inhibitors in ACE. (A) Model of Ac-SDKP 
binding to N-domain ACE (as above). The catalytic channel is represented with a transparent surface 
calculated with the program HOLLOW66 (B) Model of Ac-SDKP binding to C-domain ACE, with C-domain 
ACE in blue, and Ac-SDKP in purple. (C) Crystal structure of the N-domain specific RXP 407 inhibitor 
bound to N-domain ACE (PDB 3NXQ)30, with RXP 407 in pink. (D) Crystal structure of C-domain ACE in 
complex with AngII (PDB 4APH)31; with AngII in yellow. Non-conserved residues of the catalytic channel 
are indicated by a framed label. The residues involved in N-domain specificity30 are labelled in red.
www.nature.com/scientificreports/
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Discussion
Ac-SDKP is an important substrate of ACE that, through specific inhibition, could lead to beneficial 
therapeutic effects in the treatment of fibrosis disorders. Therefore, a thorough enzymatic and structural 
analysis would be useful in assisting our understanding of the requirements for hydrolysis of tetrapep-
tide substrates. Previous work involving Ac-SDKP kinetics involved the use of paper chromatography or 
HPLC, neither of which allow for medium to high throughput kinetic characterisation7,38,39. A modified 
fluorescamine assay was previously applied to ACE substrates of N-acetyl-AngI and substance P40,41, as 
well as to other enzyme substrates42,43. Recently, our group employed this derivatising agent to assess 
Position
N-AcSDKP Ang II31 RXP407 inhibitor30
N-domain 
ACE
Corresponding 
residues in C-ACE
Corresponding 
residues in N-ACE
C-domain 
ACE
N-domain 
ACE
Corresponding 
residues in C-ACE
S2 D336 D358
S2 Y369 F391 Y369 F391
S2 H388 H410
S1 A334 A356 A334 A356 A334 A356
S1 E362 E384 E362 E384 E362 E384
S1 T496 V518
S1′ H331 H353 H331 H353 H331 H353
S1′ A332 A354 A332 A354 A332 A354
S1′ T358 V518
S1′ H491 H513 H491 H513 H491 H513
S1′ Y501 Y523 Y501 Y523 Y501 Y523
S2′ Q259 Q281 Q259 Q281 Q259 Q281
S2′ K489 K511 K489 K511 K489 K511
S2′ Y498 Y520 Y498 Y520 Y498 Y520
Table 3.  Alignment of ACE residues involved in direct interactions with Ac-SDKP compared to the 
C-domain ACE-AngII and N-domain ACE-RXP407 complexes. Structural comparison of the two domains 
of ACE in complex with their preferred substrate (Ac-SDKP for N-domain ACE, and Ang II for C-domain 
ACE) highlights the common mechanism of peptide recognition. The model of N-domain ACE with its full 
Ac-SDKP substrate indicates that further direct interactions with N-ACE specific residues are the basis for 
its domain partiality. Additionally, several potential interactions were distinguished that were not observed 
in the N-ACE complex structure with RXP407, the most selective N-ACE inhibitor to date.
Figure 5. Proposed model for the catalytic mechanism of Ac-SDKP hydrolysis by N-domain ACE. (A) 
Model of Ac-SDKP (grey) bound to N-domain ACE (cyan) prepared as above. N-domain ACE residues 
involved in the zinc-mediated activity and stabilisation of the potential transition state intermediates are 
shown as stick. The water involved in the nucleophilic reaction is shown in red (sphere). (B) Potential role 
of the chloride ion in activity. Chloride ion is shown in green, with potential hydrogen bond and water 
mediated-interactions with the catalytic site highlighted as green dashes.
www.nature.com/scientificreports/
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simple enzyme activity of a newly identified polymorphism44. Here we employed fluorescamine to assess 
the detailed kinetics of Ac-SDKP processing by ACE.
The N-domain selectivity of Ac-SDKP processing was found to be markedly reduced compared to 
some previous reports. Literature reports differ on the degree of catalytic efficiencies and selectivities of 
Ac-SDKP hydrolysis7,38. The Km values determined in this study are generally higher than the original 
publication presenting Ac-SDKP hydrolysis as a highly N-domain specific process7 also determined Km 
values that differ depending on the enzymatic construction and methodology employed38. The selectivity 
of Ac-SDKP reported here for the individual domains (N-domain and C-domain) is only 2-fold. Deddish 
et al. also found a decrease in selectivity, with Ac-SDKP having approximately 8-fold N-selectivity38. In 
this study, the C-domain enzymes had a considerably higher turnover rate than previously described, 
thus decreasing the overall selectivity. Increased C-domain activity could be due to the assay conditions 
used here that differs to other studies, where we sought to best mimic the NaCl physiological context 
(generally 100 mM NaCl). In the original publication of the N-selectivity of Ac-SDKP processing, despite 
showing that maximal activity of both domains occurs at 100 mM NaCl, a concentration of 50 mM NaCl 
was used in the assay buffers7. Indeed, lower chloride concentrations seemed to result in increased pref-
erence for N-domain activity38. Thus, a contributor to higher C-domain activity could possibly be due 
to the use of an optimal chloride concentration for the C-domain6,37. Interestingly, the in vivo N-domain 
inactivation results in a 4–7 fold increase in plasma Ac-SDKP concentrations22,45,46. This indicates that 
the selectivity observed in the current report is consistent with more physiologically relevant observa-
tions. Importantly, while it seems that the selectivity of Ac-SDKP for the N-domain is less than originally 
reported, the in vivo studies state that the modest increase in serum peptide levels through the use of 
N- domain selective inhibitors can still possibly provide the desired therapeutic effects.
The structural basis of Ac-SDKP’s preferential hydrolysis by the N-domain was investigated by ana-
lysing the molecular interactions of the N-domain with the peptide. The two peptides occupied the 
same area of the S′ catalytic sub-pocket and displayed noticeable differences in their mode of binding 
within the S1′ site while showing common features in carboxy-terminal ends binding within with the 
S2′ sites. This common anchoring in the S2′ site is homologous to that of peptide binding in C-domain 
ACE31, and of the peptide-based N-domain inhibitors RXP 40733 and 33RE35. Surprisingly, the substrate 
binding pockets of N-domain ACE do not present any changes at all between the two structures and 
can accommodate the two very different peptides without any conformational rearrangement (Fig.  1). 
Interestingly, phosphinic inhibitors were recently showed to fit to the conserved substrate binding pocket 
of the two domains of ACE and its Drosophila homologue (AnCE) with the enzymes showing little 
plasticity47. This unspecific mechanism of peptide recognition may explain the wide range of substrates 
cleaved by this enzyme.
Using the structural information above, we were able to generate a model for Ac-SDKP binding into 
the enzyme active site and revealed the importance of the S2 site in providing possible unique interac-
tions for preferential processing. Further, it suggests a minimal set of amino acids that are responsible 
for enzyme selectivity that, if properly exploited, could result in domain selective inhibitors and/or drugs. 
Some of these residues have been implicated in selective inhibitor binding35,36 and thus this study also 
serves the prioritisation of optimal interactions with this site. The N-acetyl group is easily accommo-
dated in the cavernous S2 site with the primary contacts in this region being carried out by the P2 Ser 
of the substrate. Our structural model provides visual insight for observations of other kinetic studies, 
whereby selectivity of Ac-SDKP analogues could be influenced by changing the unprimed substrate 
amino acids while having benzoyl derivatives (considerably larger than an acetyl group) on the substrate 
N-terminus8,48. Taken together, this suggests a limited role of the acetyl group in contributing to prefer-
ential processing.
The two active sites within human and bovine somatic ACE exhibit negative co-operativity with cer-
tain, but not all, substrates26,27,49,50. The current study shows that the catalytic efficiencies of sACE in 
Ac-SDKP hydrolysis appears overall to be additive between the two domains. Similar to other kinetic 
observations with physiological substrates, such as Ang(1–9) and BK, the degree of co-operativity 
between domains in Ac-SDKP processing is considerably less than many synthetic peptides observed 
previously27,51. The sACE CC-domain enzyme possessed a catalytic ability per active site similar to 
the individual domains, indicating an additive effect between the two C-domains. The analysis of the 
CC-sACE enzyme also indicated that the N-domain has some inhibitory effect on the C-domain in 
the somatic isoform, an effect noticed in both kinetics of fluorogenic substrates and in the proteolytic 
shedding of ACE50. It seems plausible that such an effect is relevant in the physiological setting as well, 
possibly either by affecting substrate access, product release, or by reducing the overall dynamics of the 
domain required for efficient processing.
In summary, the detailed molecular interactions between Ac-SDKP and ACE were characterised. 
We have found that the tetrapeptide is indeed preferentially processed by the N-domain although this 
preference is less than some previous reports. The observations of the dipeptide fragments resulting from 
Ac-SDKP cleavage provided the structural basis to offer a complete model of domain preferential sub-
strate hydrolysis, from peptide recognition by specific domain amino acids to a detailed catalytic mech-
anism. Further, we emphasize important sets of amino acids: conserved anchoring residues that appear 
to play a role in ACE substrate binding generally and N-domain unique residues that could provide 
www.nature.com/scientificreports/
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contacts for preferential positioning. Domain interactions were also shown to influence ACE activity 
with an observed inhibitory effect of the N-domain over C-domain cleavage of Ac-SDKP. Overall, these 
findings enhance our understanding of peptide hydrolysis generally and should help the development of 
N-domain selective inhibitors that could be useful in the treatment of tissue injury and fibrosis.
Methods
Enzymes. For single, soluble enzymatic domains: a modified tACE construct, tACEΔ 36NJ, that lacks 
the transmembrane region and unique 36 amino acid N-terminus (and therefore identical to the sACE 
C-domain; hereon referred to as C-domain) had been generated previously52. A soluble form of the 
N-domain, consisting of amino acids 1 to 629 of somatic ACE (hereon referred to as N-domain), in vec-
tor pECE was a kind gift from Dr. Sergei Danilov UIC, Chicago) and was cloned into sequencing vector 
pBlueScript SK+ (Invitrogen) as previously described29,53.
The full length domain knock outs of sACE were a kind gift from Dr. Vincent Dive6. A full length 
molecule with only an active N-domain active site (N-sACE) has zinc binding residues His361 and 
His365 converted to Lys. Similarly a full length molecule with only an active C-domain active site 
(C-sACE) possesses conversions of the corresponding His residues. The CC-sACE molecule consists 
of two C-domains joined by the sACE inter-domain linker region and was constructed as described 
previously50. All full length constructs have the complete signal, transmembrane and stalk region corre-
sponding to wild type sACE.
Expression and purification of enzymes.  All enzymes were expressed in Chinese Hamster Ovary 
(CHO) cells using standard tissue culture approaches as formerly described54. All enzymes were purified 
using lisinopril-Sepharose affinity chromatography as previously described55 with the following consid-
erations: single domains were isolated from the harvest medium while full length enzymes were purified 
from whole cell triton lysates. N-domain constructs required the addition of 800 mM NaCl to medium/
lysates for effective purification56. ACE activity was detected using the substrate Cbz-Phe-His-Leu 
(Z-FHL)57 and pooled enzyme dialysed twice with 2 litres of 5 mM Hepes (pH 7.5). All enzymes were 
concentrated and stored at 4 °C in 50 mM Hepes (pH 7.5). Enzyme integrity and purity were assessed by 
SDS-PAGE and subsequent Coomassie staining.
In order to determine loss enzymatic activity due to storage, specific activities were calculated imme-
diately after purification assuming that the enzyme which is eluted off the lisinopril-Sepharose column 
must be active in order to bind the ligand. Specific activities were re-determined prior to kinetic analysis 
and active protein concentrations adjusted accordingly.
Determination of kinetic parameters. A plate adapted fluorescamine assay was employed as pub-
lished44. Thirty microlitres of AcSDKP substrate in Hepes buffer (50 mM Hepes (pH 7.5), 100 mM NaCl, 
10 μ M ZnSO4 buffer), ranging in concentration from 0 to 1000 μ M, were warmed to 37 °C in a 96-well 
plate. The assay was commenced by the addition of 10 μ l pre-warmed enzyme (0.2 pmols in Hepes 
buffer) and incubated for 15 minutes for N-domain and sACE enzymes and 30 minutes for the C-domain 
enzymes. The assay was stopped by the addition of 50 μ l 1 M HCl. The solution was neutralised by the 
addition of 50 μ l 1 M NaOH and the pH increased to 8.3 by the addition of 100 μ l 500 mM K2HPO4/
KH2PO4 buffer pH 8.3. Ten microlitres of fluorescamine (2 mg/ml in acetone, Sigma-Aldrich Co.) was 
added and the resulting mixture incubated for 3 minutes at room temperature. Fluorescence intensities 
were measured at λ ex = 390 nm and λ em = 475 nm using a Cary Eclipse spectrofluorimeter (Varian Inc.). 
Changes in fluorescence compared to unhydrolysed substrate were converted to reaction velocities by the 
use of a standard curve obtained by complete AcSDKP hydrolysis and kinetic constants calculated from 
nonlinear regression analysis (v 4.01, GraphPad Prism®). For full length ACE constructs, the presence of 
2 moles active sites for every 1 mole of enzyme was taken into account when calculating turnover rates27.
X-ray crystallography. The crystals of N-ACE in complex with the peptides were obtained by 
co-crystallization with a 2.5 mM concentration of Ac-SDKP (Biorbyt, orb70378). Crystals were grown 
with 1 μ l of the N-ACE:Ac-SDKP sample (protein at 8 mg/ml in 50 mm HEPES, pH 7.5, 0.1 mm PMSF) 
mixed with an equal volume of reservoir solution consisting of 30% PEG550 MME/PEG20000, 100 mM 
Tris/Bicine, pH 8.5, and 0.06 M divalent cations (Molecular Dimensions) and suspended above the well 
as a hanging drop.
X-ray diffraction data were collected on station IO3 at the Diamond Light Source (Oxon, UK) equipped 
with a PILATUS-6M detector (Dectris, Switzerland). Crystals were kept at constant cryo-temperature 
(100 K) during data collection. Raw data images were processed and scaled with MOSFLM58, and 
SCALA using the CCP4 suite 6.559. Molecular replacement with the coordinates of N-domain (PDB code 
3NXQ)30 was used to determine initial phases for structure solution in PHASER60. The working models 
were refined using REFMAC561 and manually adjusted with COOT62. Water molecules were added at 
positions where Fo − Fc electron density peaks exceeded 3σ , and potential hydrogen bonds could be 
made. Validation was performed with MOLPROBITY63. Crystallographic data statistics are summarized 
in Table 1. All figures were drawn with PyMOL (Schrödinger, LLC, New York). Hydrogen bonds were 
verified with the program LigPlot+ 64.
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